報價延遲最少15分鐘:2026/04/16 05:38 EDT
盤前時段
|
||||
|
7.28 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.66
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.56/-1.43
|
|
企業價值
213.86M
|
| 資產負債 |
|
每股賬面淨值
3.58
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
34.26M
|
|
每股收益
2.03
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")). |
